COTA, Inc. named a 2020 Fast 50 company by Boston Business Journal
The Boston Business Journal has named COTA, Inc. to its exclusive 2020 Fast 50 list, which represents the 50 fastest-growing private companies in Massachusetts.
Historical Regulatory Use of RWE
Historical uses of RWE in regulatory decision-making are at best sparse, but they provide the precedent on which we are building the foundation of real-world impact. This blog reviews use cases of RWE in regulatory actions.
Managing COVID-19 Among Cancer Patients: Risk & Response
New research shows that cancer patients may be more susceptible to COVID-19 than individuals without cancer, and have poorer outcomes.
COVID-19 & COTA: Perspectives from Mike Doyle, CEO
Reflecting on the weeks ahead as we try to prevent the spread of COVID-19, COTA’s CEO Mike Doyle shares some of the things we’re doing to support our team members at COTA, and highlights promising industry developments.
COTA Team Member Spotlight: The Women of COTA
In honor of International Women’s Day this month, we want to recognize the female colleagues who inspire us to work harder, collaborate more, and fiercely support each other.
COTA Appoints C.K. Wang, M.D. as New Chief Medical Officer
Dr. Wang’s Commitment to COTA’s Mission and Extensive Oncology Background Supports The Company’s Next Stage of Growth and Ongoing Partnerships
COTA Team Member Spotlight: Irfan Shah
For this month’s Team Member Spotlight, we are excited to introduce you to Irfan Shah! Irfan joined COTA in 2016 and is the company’s Director of Strategy and Business Development for life sciences.
White Paper: Real-World Evidence Reflections and Predictions
Novel sources and growing volumes of data are changing the way drugs are developed, evaluated, and brought to market. In the spirit of collaboration, COTA invited our partners from Pfizer and Bristol-Myers Squibb to share their unique perspectives as early adopters of real-world evidence.
FierceHealthcare names COTA, Inc. as one of its 2020 “Fierce 15” Companies
COTA, Inc. has been named by FierceHealthcare as one of the 2020 Fierce 15 Companies, designating it as one of the most promising healthcare companies in the industry.
CEO Corner: COTA’s Year in Review
At COTA, 2019 represented a year of collaboration, research, and innovation to advance the use of real-world evidence in cancer care and drug development. As we think about what’s ahead in 2020, COTA’s CEO Mike Doyle reflects on how activities this year set us up for future success and continued learning.
